Erythromycin (CAS No.: 114-07-8) - Macrolide Antibacterial for Gram-Positive & Atypical Infections

As a professional supplier of pharmaceutical-grade and veterinary-grade antibacterial active ingredients, we provide high-purity Erythromycin that strictly complies with global pharmacopoeia standards (USP, EP, BP, CP). A natural macrolide antibiotic derived from Streptomyces erythreus, it exhibits potent bacteriostatic (and bactericidal at high doses) activity against Gram-positive bacteria and atypical pathogens. It is widely used in human medicine for treating respiratory, skin, and soft tissue infections-especially in patients allergic to penicillins-and in veterinary practice for livestock and companion animals, serving as a foundational agent in antibacterial therapy.

Product Basic Information

Core Functions & Mechanism of Action

Erythromycin exerts its antibacterial effect by targeting the bacterial ribosome, inhibiting protein synthesis-critical for bacterial growth and survival:

Ribosome Binding:is binds reversibly to the 50S subunit of the bacterial ribosome, specifically interacting with the 23S rRNA and ribosomal proteins L4 and L22.

Protein Synthesis Blockade: This binding prevents the translocation step of protein synthesis-blocking the movement of the ribosome along mRNA and halting the addition of new amino acids to the growing peptide chain.

Bacteriostatic/Bactericidal Activity: At standard doses, it suppresses bacterial growth (bacteriostatic); at high doses or against susceptible strains (e.g., Streptococcus pneumoniae), it can kill bacteria (bactericidal) by disrupting membrane integrity.

Key antibacterial spectrum advantages:

Gram-Positive Coverage: Active against Staphylococcus aureus (MSSA), Streptococcus pyogenes (Group A strep), Streptococcus pneumoniae, and Corynebacterium diphtheriae-ideal for penicillin-allergic patients.

Atypical Pathogen Coverage: Effective against Mycoplasma pneumoniae, Chlamydophila pneumoniae, Chlamydia trachomatis, and Legionella pneumophila-critical for respiratory and sexually transmitted infections (STIs).

Gram-Negative Coverage: Inhibits select Gram-negative bacteria like Haemophilus influenzae and Neisseria gonorrhoeae (though not first-line for these pathogens).

Core Applications

Erythromycin CAS#114-07-08 is administered orally (tablets, capsules, suspensions) or topically (ointments, eye drops); parenteral formulations (IV) are also available for severe infections. It is not active against viral infections (e.g., cold/flu) or Gram-negative rods (e.g., E. coli, Klebsiella).

1. Human Pharmaceutical Field

1.1 Respiratory Tract Infections

Community-Acquired Pneumonia (CAP): Treats CAP caused by Mycoplasma pneumoniae, Chlamydophila pneumoniae, or penicillin-sensitive S. pneumoniae (penicillin-allergic patients). Oral dose: 500 mg every 6 hours or 1 g every 12 hours for 7–14 days; IV dose: 500 mg–1 g every 6 hours for severe cases.

Acute Pharyngitis/Tonsillitis: For Streptococcus pyogenes infections (penicillin-allergic patients). Oral dose: 250 mg every 6 hours for 10 days (prevents rheumatic fever).

Legionnaires' Disease: First-line therapy for Legionella pneumophila infections. IV/oral dose: 1–2 g daily (divided into 4 doses) for 10–14 days.

1.2 Skin & Soft Tissue Infections

Impetigo & Cellulitis: Treats Staphylococcus aureus or Streptococcus pyogenes infections. Oral dose: 250–500 mg every 6 hours for 7–10 days; topical ointment (2%) applied 3–4 times daily for mild cases.

Diphtheria: Adjuvant therapy to diphtheria antitoxin, eliminating Corynebacterium diphtheriae from the throat. Oral dose: 250–500 mg every 6 hours for 14 days.

1.3 Sexually Transmitted Infections (STIs)

Chlamydia Trachomatis Infections: Treats urethritis, cervicitis, or pelvic inflammatory disease (PID) in patients allergic to azithromycin. Oral dose: 500 mg twice daily for 7 days.

Gonorrhea: Alternative therapy for Neisseria gonorrhoeae (when first-line agents are unavailable). Oral dose: 500 mg every 6 hours for 7 days (combined with probenecid for enhanced efficacy).

1.4 Topical Infections

Ophthalmic Infections: Eye ointment (0.5%) for bacterial conjunctivitis (e.g., Haemophilus influenzae, Staphylococcus aureus)-applied 1–2 times daily for 7–10 days.

Acne Vulgaris: Topical gel/ointment (2%) for mild-to-moderate acne, reducing Cutibacterium acnes colonization-applied once daily.

2. Veterinary Field (Livestock & Companion Animals)

CAS#114-07-08 is used to treat bacterial infections in cattle, pigs, chickens, dogs, and cats:

Bovine Respiratory Disease (BRD): Caused by Mannheimia haemolytica or Mycoplasma bovis. IM/oral dose: 10–20 mg/kg body weight once daily for 3–5 days.

Porcine Respiratory Disease Complex (PRDC): For Mycoplasma hyopneumoniae or Streptococcus suis infections. Oral dose: 20–40 mg/kg feed for 7–10 days.

Poultry Chronic Respiratory Disease (CRD): Treats Mycoplasma gallisepticum infections in chickens. Oral dose: 10–20 mg/kg drinking water for 5–7 days.

Canine/Feline Skin & Ear Infections: For Staphylococcus pseudintermedius (skin) or Mycoplasma spp. (ears). Oral dose: 10–20 mg/kg twice daily for 7–14 days; topical ear drops (0.5%) applied twice daily.

Contraindications: Avoid use in horses (colitis risk) or animals with pre-existing hepatic impairment; not approved for dairy cattle producing milk for human consumption.

Quality & Safety Assurance

As a widely used macrolide antibiotic, Erythromycin CAS#114-07-08 requires strict quality control to ensure potency, purity, and safety-especially given its potential for gastrointestinal side effects and drug interactions:

1. Manufacturing & Purity Control

Production: Produced via microbial fermentation of Streptomyces erythreus, followed by purification (solvent extraction, chromatography) and crystallization. The process ensures:

Minimal impurities (e.g., degradation products, related macrolides) ≤1.0% (pharmaceutical grade);

Consistent potency (950–1050 μg/mg) for reliable therapeutic effect.

GMP Compliance: Pharmaceutical-grade Erythromycin CAS#114-07-08 is manufactured in Grade D cleanrooms (per ICH Q7 guidelines); veterinary grade complies with GMP for animal pharmaceuticals.

2. Comprehensive Testing Protocol

3. Safety Reminders

Human Use:

Contraindications: Hypersensitivity to macrolide antibiotics; history of QT interval prolongation (avoid with antiarrhythmic drugs like amiodarone); severe hepatic impairment.

Adverse Effects: Common: gastrointestinal upset (nausea, diarrhea, abdominal pain) (mitigated with enteric-coated formulations); rare but serious: cholestatic jaundice (reversible upon discontinuation), ototoxicity (high doses).

Drug Interactions: Inhibits CYP3A4 enzymes-avoid concurrent use with warfarin (increased bleeding risk), simvastatin (rhabdomyolysis risk), or cyclosporine (increased nephrotoxicity risk).

Veterinary Use:

Withdrawal Periods: Cattle: 21 days (meat); Pigs: 14 days (meat); Chickens: 7 days (meat/eggs); Dogs/Cats: No withdrawal period (non-food animals).

Residue Warning: Prohibited in dairy cattle (milk residues) and laying hens (egg residues) beyond the withdrawal period.

Cooperation & Contact

We supply Erythromycin in grades and forms tailored to human and veterinary applications:

Pharmaceutical Grade: Fine powder or enteric-coated granules (1kg–100kg per order, sealed aluminum foil bags with desiccants) for oral/topical formulations.

Veterinary Grade: Powder for livestock oral premixes or injectables (10kg–500kg per order; monthly production capacity of 2500kg).

Value-added services include:

Providing DMF (Drug Master File) and CEP (Certificate of Suitability) for pharmaceutical-grade products to support EU/US/Asia registration.

Technical support for enteric coating (reducing gastrointestinal side effects) and veterinary formulation stability testing.

Batch-specific COA with purity, assay, and residual solvent results to ensure regulatory compliance.

If you are a pharmaceutical manufacturer, nutraceutical brand, or veterinary drug enterprise, please contact us for detailed cooperation:

Contact Information:

Email: sales@huarongpharma.com

Phone/WhatsApp: +86 13751168070

We adhere to the principles of "antibacterial efficacy, safety compliance, and versatility" and look forward to partnering with global healthcare and animal health industries!

Hot Tags: erythromycin cas#114-07-08, China erythromycin cas#114-07-08 manufacturers, suppliers, api endpoints, api for data analytics, api for defense, api for public relations, api for search engine marketing, open api